Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-25-030080
Filing Date
2025-02-28
Accepted
2025-02-28 16:30:38
Documents
1
Period of Report
2025-02-27

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 3229
  Complete submission text file 0000950170-25-030080.txt   4724
Mailing Address 41 SEYON STREET BUILDING 1, SUITE 100 WALTHAM MA 02453
Business Address 41 SEYON STREET BUILDING 1, SUITE 100 WALTHAM MA 02453 7814499560
REPLIGEN CORP (Issuer) CIK: 0000730272 (see all company filings)

EIN.: 042729386 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O REPLIGEN CORPORATION 41 SEYON STREET, BUILDING 1, SUITE 100 WALTHAM MA 02453
Business Address
Loeillot Olivier (Reporting) CIK: 0001995525 (see all company filings)

Type: 4 | Act: 34 | File No.: 000-14656 | Film No.: 25690910